<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332173</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111-210</org_study_id>
    <secondary_id>CTR20170208</secondary_id>
    <nct_id>NCT03332173</nct_id>
  </id_info>
  <brief_title>Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)</brief_title>
  <official_title>A Phase 2, Single-Arm, Open-Label, Multicenter Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity
      or death, withdrawal of consent, lost to follow-up, or study termination from sponsor;
      treatment (up to 3 years), safety follow up (28 days); survival follow-up until data cutoff
      for final analysis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 31, 2017</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major response rate(MRR)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>defined as complete response(CR) + very good partial response(VGPR) + partial response(PR), to be assessed by an independent review committee (IRC) according to an adaptation of the response criteria updated at the 6th Workshop on Waldenström's Macroglobulinemia (IWWM, Owen et al 2013 and NCCN Guidelines, Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia 2015: v2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>defined as time from first dose of BGB-3111 until first documentation of progression (by IWWM criteria) or death, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>ORR is the proportion of subjects with a minor, partial, very good partial, and complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of major response (DOMR)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>defined as the time from the date that the major response criteria are first met to the date that progressive disease (PD) is objectively documented or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of treatment precipitating symptoms</measure>
    <time_frame>up to 3 years</time_frame>
    <description>defined as absence of symptoms at any point during study treatment, which triggered the initiation of study treatment as per the IWWM treatment guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-lymphoma effect</measure>
    <time_frame>up to 3 years</time_frame>
    <description>defined as any reduction during the course of study treatment in bone marrow involvement by lymphoplasmacytoid lymphocytes and/or size of lymphadenopathy and/or hepatosplenomegaly by CT scan. Lymphadenopathy is defined as any node with longest diameter (LDi) &gt; 1.5 cm and splenomegaly is defined as vertical spleen length &gt; 13 cm.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Waldenström's Macroglobulinemia (WM)</condition>
  <arm_group>
    <arm_group_label>BGB-3111</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-3111</intervention_name>
    <description>BGB-3111 160 mg twice daily(BID) (in 80 mg white opaque capsules) administered orally</description>
    <arm_group_label>BGB-3111</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical and definitive histologic diagnosis of WM (Gertz et al 2017), meeting at
             least one criterion for treatment according to consensus panel criteria from the
             Seventh IWWM (Dimopoulos et al 2014).

          2. WM pathology confirmation by central lab prior to study enrollment. Previous pathology
             report, concurrently with newly generated central lab report to be reviewed to support
             WM diagnosis.

          3. Men and women ≥ 18 years of age.

          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

          5. Previously treated with a minimum of 1 prior line of standard chemotheraphy-containing
             regimen(with completion of ≥ 2 continuous treatment cycles

          6. Documented failure to achieve at least minor response or documented disease
             progression after response to the most recent treatment regimen.

          7. Neutrophils ≥ 0.75 x 10^9/L independent of growth factor support within 7 days of
             first dose.

          8. Platelets ≥ 50 x 10^9/L, independent of growth factor support or transfusion within 7
             days of first dose.

          9. Hemoglobin≥80g/L, independent of erythropoietin (EPO) support or transfusion within 7
             days of first dose of study drug.

         10. Creatinine clearance of ≥ 30 mL/min (as estimated by the Cockcroft-Gault equation
             (Cockcroft and Gault 1976) or estimated glomerular filtration rate [eGFR] from the
             Modification of Diet in Renal Disease [MDRD]).

         11. AST and ALT ≤ 3.0 x ULN.

         12. Bilirubin ≤ 2 x ULN (unless documented Gilbert's syndrome).

         13. INR ≤ 1.5 and APTT ≤ 1.5 x ULN. Patients with lupus anticoagulant or acquired von
             Willebrand disease due to WM may be enrolled after discussion with the medical
             monitor.

         14. ECHO must demonstrate left ventricular ejection fraction (LVEF) ≥50% (AHA,2016).

         15. Subjects may be enrolled who relapse after autologous stem cell transplant if they are
             at least 6 months after transplant at screening. To be eligible after transplant,
             subjects should have no active related infections.

         16. Females of childbearing potential must agree to use highly effective forms of birth
             control throughout the course of the study and at least up to 90 days after last dose
             of study drug. Highly effective forms of birth control can be defined as abstinence,
             hysterectomy, bilateral oophorectomy with no menstrual bleeding for up to 6 months,
             intrauterine contraception, hormonal methods such as contraceptive injection, oral
             contraceptive, etc. Males must have undergone sterilization-vasectomy, or use a
             barrier method where the female partner uses the effective forms of birth control
             noted above and must not donate sperm for at least 90 days after last dose of study
             drug.

         17. Life expectancy of &gt; 4 months.

         18. Able to provide written informed consent and can understand and comply with the
             requirements of the study.

        Exclusion Criteria:

          1. Central nervous system (CNS) involvement by WM.

          2. Prior exposure to a BTK inhibitor.

          3. Evidence of disease transformation.

          4. Prior corticosteroids given in excess of prednisone 10 mg/day or its equivalent with
             antineoplastic intent within 7 days, prior chemotherapy, targeted therapy, or
             radiation therapy within 3 weeks, antineoplastic therapy with Chinese herbal medicine
             or antibody based theratpies within 4 weeks of the start of study drug.

          5. Major surgery within 4 weeks of randomization.

          6. Toxicity of ≥Grade 1 from prior anti-cancer therapy (except for absolute neutrophil
             count [ANC] and platelets. For ANC and platelets, please follow inclusion criteria #7
             [neutrophils] and #8 [platelets]).

          7. History of other active malignancies within 2 years of study entry, with exception of
             (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or
             squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally
             (surgery or other modality) with curative intent.

          8. Currently active clinically significant cardiovascular disease such as uncontrolled
             arrhythmia, uncontrolled hypertension, congestive heart failure, any Class 3 or 4
             cardiac disease as defined by the New York Heart Association (NYHA) Functional
             Classification, or history of myocardial infarction within 6 months of screening.

          9. QTcF prolongation (defined as a QTc &gt;480 msecs based on Fridericia's formula) or other
             significant ECG abnormalities including second degree atrioventricular (AV) block Type
             II, or third degree AV block.

         10. Unable to swallow capsules or disease significantly affecting gastrointestinal
             function such as malabsorption syndrome, resection of the stomach or small bowel,
             symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.

         11. Active infection including infections requiring oral or intravenous anti-microbial
             therapy.

         12. Known human immunodeficiency virus (HIV), or active hepatitis B or hepatitis C
             infection (detected positive by polymerase chain reaction [PCR]).

         13. Pregnant or lactating women.

         14. Any life-threatening illness, medical condition or organ system dysfunction which, in
             the investigator's opinion, could compromise the subject's safety, or put the study at
             risk.

         15. On medications which are strong CYP3A inhibitors or strong CYP3A inducers.

         16. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.

         17. Has received allogenic hematopoietic stem cell transplantation prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>male and female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lugui Qiu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology &amp; Blood Diseases Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Pepole's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 2, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>November 29, 2019</last_update_submitted>
  <last_update_submitted_qc>November 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

